Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: Future directions

Csaba Szabó

    Research output: Contribution to journalReview articlepeer-review

    18 Scopus citations


    Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in the upcoming few years, clinical proof of PARP inhibitors' therapeutic effect will be obtained in human disease. Acute, life-threatening cardiovascular diseases (myocardial infarction, cardiopulmonary bypass in high-risk patients, and other, severe forms of ischemia-reperfusion to other organs including stroke and thoracoabdominal aneurysm repair) represent some of the initial development indications for PARP inhibitors.

    Original languageEnglish (US)
    Pages (from-to)301-303
    Number of pages3
    JournalCurrent Vascular Pharmacology
    Issue number3
    StatePublished - Jul 1 2005


    • Acute
    • Apoptosis
    • Blood vessels
    • Chronic
    • DNA repair
    • Drug development
    • Inflammation
    • Myocardial infarction
    • Necrosis
    • Stroke

    ASJC Scopus subject areas

    • Pharmacology
    • Cardiology and Cardiovascular Medicine


    Dive into the research topics of 'Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: Future directions'. Together they form a unique fingerprint.

    Cite this